• Upstream process development for expression of protein therapeutics in novel SoluPro™ E. coli• Trained team of research associates and scientists on operating and analyzing data from AMBR250, AMBR15, Eppendorf DASbox, and Bioengineering NLF bioreactors• Demonstrated process scalability to 30L fermenters and prepared data for tech transfer to CDMO• Designed and performed DOE studies on fermentation media and induction conditions• Analyzed metabolites, titer, and online data using JMP and presented reports for fermentation runs• Developed and improved operating checklists and SOPs for fermentation activities• Tracked process deviations and improved workflows• Presented at university career receptions and interviewed scientist and intern candidates

• Designed and performed E. coli fermentation experiments for expression of protein therapeutics in AMBR250 bioreactors, 250 mL DASbox reactors and scale up to 30L Bioengineering NLF reactors

Developed fermentation scale down models for media optimization and performed DOEs using JMP software.

• Performed DOE studies to optimize drying and cleaning conditions of tank surfaces, resulting in improved clean in place protocols• Collected and analyzed buffer manufacture process data to implement new process tolerances and improved SOP, resulting in removal of a bottleneck process step• Investigated root causes of buffer manufacture trends

• Investigated immobilized peptides for use in microfluidic hemoperfusion devices to treat severe sepsis• Developed assays for measuring selective removal of endotoxin and bacterial cells with immobilized endotoxin-binding peptides• Engineered recombinant endotoxin binding phage proteins using amber codon genetic code expansion techniques to incorporate non-canonical amino acids

• Investigated transcription factor proteolysis in the bacterial stress response in Bacillus subtilis• Used site-directed mutagenesis to understand proteolysis mechanism for regulation of transcription factor